welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD
study id #: NCT04060199
condition: Duchenne Muscular Dystrophy
status: recruiting
purpose:The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
intervention: Viltolarsen, Placebo
mechanism of action: Exon-skipping to promote dystrophin production
results: https://clinicaltrials.gov/ct2/show/results/NCT04060199
last updated: December 10, 2019
rareRelated
-
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular D...FibroGen, Inc., a leading biopharmaceu...
-
Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB PatientsThe purpose of this study is to evaluate...
-
An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (GalaxyDMD)The GalaxyDMD study is a global Phase 3,...
-
A Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
-
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)This is a Phase 2, open-label, single ar...
-
FDA grants RASRx1902 orphan drug status as potential therapy for Duchenne muscular dystrophyThe U.S. Food and Drug Administration ha...
-
Rimeporide in Patients With Duchenne Muscular DystrophyIn Duchenne Muscular Dystrophy (DMD) the...
-
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
-
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients With Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...
-
Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dy...Background: Edasalonexent is an orally ...